Role of sodium l-cysteine alginate conjugate and isopropyl myristate to enhance the permeation enhancing activity of BCS class III drug from TDDS; optimization by central composite design and in vivo pharmacokinetics study

References

• Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev. 2005;11(3):253–272.
   PubMedGoogle Scholar
• Zesiewicz TA, Chriscoe S, Jimenez T, et al. A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease. Neurodegener Dis Manag. 2017;7(1):49–59.
   PubMed Web of Science ®Google Scholar
• Sweetman SC. Martindale: the complete drug reference. 38th ed. London: Pharmaceutical Press; 2014.
   Google Scholar
• Sachan NK, Pushkar S, Jha A, et al. Sodium alginate: the wonder polymer for controlled drug delivery. J Pharm Res. 2009;2(8):1191–1199.
   Google Scholar
• Robouch P, Von Holst C. Evaluation report on the analytical methods submitted in connection with the application for the authorisation of feed additives according to regulation (EC) No. 1831/2003; European commission. Belgium: JRC Geel; 2018.
   Google Scholar
• Pillay V, Seedat A, Choonara YE, et al. A review of polymeric refabrication techniques to modify polymer properties for biomedical and drug delivery applications. AAPS PharmSciTech. 2013;14(2):692–711.
   PubMed Web of Science ®Google Scholar
• Zhu X, Su M, Tang S, et al. Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis. 2012;18:1973–1982.
   PubMed Web of Science ®Google Scholar
• DeMaagd G, Philip A. Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm Ther. 2015;40(8):504–532.
   Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Qamar MA, Rajah T, et al. Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future. NPJ Parkinsons Dis. 2016;2:16023.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. Prim Care Companion CNS Disord. 2011;13(6):PCC.11r01149.
   PubMedGoogle Scholar
• Isaac M, Holvey C. Transdermal patches: the emerging mode of drug delivery system in psychiatry. Ther Adv Psychopharmacol. 2012;2(6):255–263.
   PubMedGoogle Scholar
• Akhtar N, Pathak K. Feasibility assessment of transdermal drug delivery systems for treatment of Parkinson's disease. Ann Pharmacol Pharm. 2017;2(9):1090.
   Google Scholar
• Sadashivaiah R, Rohith G, Satheesh Babu BK. Quantification of ropinirole hydrochloride in API and tablets by novel stability-indicating RP-HPLC method: it’s validation and forced degradation studies. Int J App Pharm. 2019;11(5):293–323.
   Google Scholar
• Dinesh BM, Patil UA, Desai BG, et al. Design and in vitro evaluation of haloperidol lactate transdermal patches containing ethyl cellulose-povidone as film formers. Asian J Pharm. 2008;2(1):43–49.
   Google Scholar
• Satheeshababu BK, SrinivasaRao K. Synthesis and characterization of sodium alginate conjugate: preparation and evaluation of transdermal patches of losartan potassium using sodium alginate conjugate. Thai J Pharm Sci. 2015;39(1):10–20.
   Google Scholar
• Thermo Scientific. DTNB (Ellman's Reagent) (5,5-dithio-bis-(2-nitrobenzoic acid). Rockford (IL): Pierce Biotechnology; 2015. Available from: https://www.thermofisher.com/order/catalog/product/22582/User Guide/MAN0011216_ Ell mans_Reag_UG.pdf
   Google Scholar
• Rastogi V, Yadav P, Husain A, et al. Effect of hydrophilic and hydrophobic polymers on permeation of S-amlodipine besylate through intercalated polymeric transdermal matrix: 3(2) designing, optimization and characterization. Drug Dev Ind Pharm. 2019;45(4):669–682.
   PubMed Web of Science ®Google Scholar
• Taghizadeh SM, Moghimi-Ardakani A, Mohamadnia F. A statistical experimental design approach to evaluate the influence of various penetration enhancers on transdermal drug delivery of buprenorphine. J Adv Res. 2015;6(2):155–162.
   PubMed Web of Science ®Google Scholar
• Parhi R, Panchamukhi T. RSM-based design and optimization of transdermal film of ondansetron HCl. J Pharm Innov. 2020;15(1):94–109.
   Web of Science ®Google Scholar
• Malaiya MK, Jain A, Pooja H, et al. Controlled delivery of rivastigmine using transdermal patch for effective management of Alzheimer's disease. J Drug Deliv Sci Technol. 2018;45:408–414.
   Web of Science ®Google Scholar
• Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm. 2013;39(1):39–50.
   PubMed Web of Science ®Google Scholar
• Akram MR, Ahmad M, Abrar A, et al. Formulation design and development of matrix diffusion controlled transdermal drug delivery of glimepiride. Drug Des Dev Ther. 2018;12:349–364.
   PubMed Web of Science ®Google Scholar
• European Pharmacopoeia. Microbiological quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use. European Pharmacopoeia Commission. European Directorate for the Quality of Medicines & Healthcare, Council of Europe. 2017.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A (R2), Geneva. 2003.
   Google Scholar
• Islam J, Zaman K, Chakrabarti S, et al. Exploration of ethyl anthranilate-loaded monolithic matrix-type prophylactic polymeric patch. J Food Drug Anal. 2017;25(4):968–975.
   PubMed Web of Science ®Google Scholar
• Gfeller W, Kobel W, Seifert G. Overview of animal test methods for skin irritation. Food Chem Toxicol. 1985;23(2):165–168.
   PubMed Web of Science ®Google Scholar
• Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–390.
   Web of Science ®Google Scholar
• Ghosh MN. Fundamentals of experimental pharmacology. 3rd ed. Kolkata: Hilton & Company. 2005; p. 190–194.
   Google Scholar
• Azeem A, Talegaonkar S, Negi LM, et al. Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm. 2012;422(1–2):436–444.
   PubMed Web of Science ®Google Scholar
• Malewar N, Avachat M, Pokharkar V, et al. Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. AAPS PharmSciTech. 2013;14(3):1178–1189.
   PubMed Web of Science ®Google Scholar
• Jasti BR, Abraham W, Ghosh TK. Transdermal and topical drug delivery systems. In: Ghosh TK, Jasti BR, editors. Theory and practice of contemporary pharmaceutics. 1st ed. Florida: CRC Press; 2005. p. 423–454.
   Google Scholar
• Zhao C, Quan P, Liu C, et al. Effect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserin. Acta Pharm Sin B. 2016;6(6):623–628.
   PubMed Web of Science ®Google Scholar
• Liu H, Jiang J, Wang H, et al. A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2014;3(2):84–92.
   PubMed Web of Science ®Google Scholar
• Gupta SU, Kaur JA, Verma RA. Study on formulation and evaluation of ropinirole hydrochloride loaded microspheres using polymers blend of ethyl cellulose and carbopol 934P. Int J Curr Res Chem Pharm Sci. 2014;1(5):48–55.
   Google Scholar
• Pardeshi CV, Belgamwar VS. Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation. Artif Cells Nanomed Biotechnol. 2017;45(3):635–648.
   PubMed Web of Science ®Google Scholar